REGENERON PHARMACEUTICALS, INC. Share-Based Compensation 2008-2026 | REGN
What is share-based compensation?
Share-based compensation is the non-cash expense of stock options, restricted stock units, and other equity awards granted to employees.
What is REGENERON PHARMACEUTICALS, INC.'s current share-based compensation?
REGENERON PHARMACEUTICALS, INC. (REGN) annual share-based compensation for 2025 was $993.7M, a 1.11% increase from 2024. REGENERON PHARMACEUTICALS, INC. share-based compensation for the quarter ending March 31, 2026 was $257.4M.
What was REGENERON PHARMACEUTICALS, INC.'s share-based compensation in 2024?
REGENERON PHARMACEUTICALS, INC. annual share-based compensation for 2024 was $982.8M, a 11.05% increase from 2023.
What was REGENERON PHARMACEUTICALS, INC.'s share-based compensation in 2023?
REGENERON PHARMACEUTICALS, INC. annual share-based compensation for 2023 was $885.0M, a 22.07% increase from 2022.
What is REGENERON PHARMACEUTICALS, INC.'s 5-year share-based compensation CAGR?
REGENERON PHARMACEUTICALS, INC. share-based compensation grew at a compound annual growth rate (CAGR) of 18.13% from FY2020 to FY2025, going from $432.0M to $993.7M over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $993.7M | +1.1% | 10-K |
| FY2024 | $982.8M | +11.1% | 10-K |
| FY2023 | $885.0M | +22.1% | 10-K |
| FY2022 | $725.0M | +20.5% | 10-K |
| FY2021 | $601.7M | +39.3% | 10-K |
| FY2020 | $432.0M | -7.0% | 10-K |
| FY2019 | $464.3M | +8.6% | 10-K |
| FY2018 | $427.4M | -15.8% | 10-K |
| FY2017 | $507.3M | -9.4% | 10-K |
| FY2016 | $559.9M | +22.0% | 10-K |
| FY2015 | $459.0M | +42.7% | 10-K |
| FY2014 | $321.8M | +49.4% | 10-K |
| FY2013 | $215.4M | +128.7% | 10-K |
| FY2012 | $94.2M | +67.9% | 10-K |
| FY2011 | $56.1M | +40.6% | 10-K |
| FY2010 | $39.9M | +27.6% | 10-K |
| FY2009 | $31.3M | -3.9% | 10-K |
| FY2008 | $32.5M | - | 10-K |